Which Company Outperformed All Other Biotechs in August?

Published: Sep 05, 2012

Sarepta, the developer of a new muscular dystrophy drug with extremely promising results, saw its shares gain more than any other medical stock in my monthly scan of biotech, pharma, and medical device stocks. This scan, using data from Interactive Data and Thomson Reuters Fundamentals via FactSet Research Systems, includes companies that have a market capitalization of more than $300 million at the beginning or end of the period from the close on July 31 to the close on Aug. 31.

Back to news